Clinical Trial Update: To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SAL056 for postmenopausal osteoporosis at high fracture risk has completed; the snippet does not provide efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• SAL056

Snippet

Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. | Conditions: Postmenopausal Women With Osteoporosis | Phase 3 | Status: COMPLETED